Previous close | 25.44 |
Open | 25.15 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 25.12 - 25.74 |
52-week range | 25.12 - 25.74 |
Volume | |
Avg. volume | N/A |
Market cap | N/A |
Beta (5Y monthly) | 1.05 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
EQS-News: Evotec SE / Key word(s): Annual ReportEvotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023 12.05.2023 / 23:55 CET/CESTThe issuer is solely responsible for the content of this announcement. PUBLICATION OF ANNUAL REPORT 2022: “AHEAD OF THE CURVE” QUALITATIVE QUARTERLY STATEMENT FOR THE FIRST QUARTER OF 2023 GUIDANCE FOR FY2023 AND MID-TERM GUIDANCE FOR 2025 UNCHANGED Hamburg, Germany, 12 May 2023:Evotec SE (Frankfurt Stock Exchange: Prime Standard, ISIN: DE0005664809;
EQS-News: Evotec SE / Key word(s): MiscellaneousJust – Evotec Biologics launches tech partnership for biosimilars development and commercial manufacturing 09.05.2023 / 20:07 CET/CESTThe issuer is solely responsible for the content of this announcement. JUST – EVOTEC BIOLOGICS AND SANDOZ JOIN FORCES TO DEVELOP AND MANUFACTURE A DEFINED PORTFOLIO OF BIOSIMILAR MOLECULES JUST – EVOTEC BIOLOGICS TO RECEIVE DOUBLE-DIGIT-MILLION UPFRONT, FUTURE PAYMENTS DEPENDENT ON SUCCESSFUL DEVELOPMENT PROGRESS OF
Evotec SE / Key word(s): MiscellaneousJust – Evotec Biologics enters strategic biosimilars partnership with Sandoz09-May-2023 / 20:05 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec SE provides update on cyber attack 10.04.2023 / 14:00 CET/CESTThe issuer is solely responsible for the content of this announcement. Business continuity upheld at all global sites after cyber attack Forensic examination ongoing with external experts Hamburg, Germany, 10 April 2023:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced an update on the cyber attack that was detected on 06 April
Evotec SE / Key word(s): MiscellaneousCyber Attack on Evotec07-Apr-2023 / 15:10 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that on 06 April, 2023 a cyber attack occurred on Evotec‘s IT
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership 28.03.2023 / 11:02 CET/CESTThe issuer is solely responsible for the content of this announcement. 8-YEAR EXTENSION AND EXPANSION OF ONGOING COLLABORATION TO DEVELOP A BROADENED PROGRAMME PIPELINE IN NEURODEGENERATIVE DISEASES PARTNERSHIP LEVERAGES EVOTEC’S PRECISION MEDICINE PLATFORMS FINANICAL TERMS INCLUDE $ 50 M UPFRONT PAYMENT, PERFORMANCE MILESTONES AND T
Evotec SE / Key word(s): MiscellaneousEvotec and Bristol Myers Squibb expand strategic neurodegeneration partnership28-March-2023 / 11:01 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces today
EQS-News: Evotec SE / Key word(s): Annual ResultsEvotec SE preliminary fiscal year 2022 results: 'Ahead of the curve' – very strong performance in a challenging year 28.03.2023 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. 22% INCREASE IN GROUP REVENUES; EBITDA EXCLUDING M&A AT € 104.1 M POSITIVE MOMENTUM AND OUTLOOK FOR 2023 DATA-DRIVEN PLATFORMS RESULTING IN LARGEST ALLIANCE IN TARGETED PROTEIN DEGRADATION IN THE INDUSTRY Hamburg, Germany, 28 March 2023
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec receives US$ 6.6 m grant for drug discovery in tuberculosis 24.03.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement. GRANT FROM THE BILL & MELINDA GATES FOUNDATION SUPPORTS EVOTEC’S EFFORTS TO DISCOVER AND DEVELOP DRUG CANDIDATES FOR A UNIVERSAL, SHORTER, SAFER AND SIMPLER TUBERCULOSIS DRUG REGIMEN AS ONE OF ITS PROGRAMMES CONTRIBUTING TO THE UN SUSTAINABLE DEVELOPMENT GOAL 3 “WORLD TUBERCULOSIS DAY”,
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec SE to announce preliminary financial results for fiscal year 2022 on 28 March 2023 21.03.2023 / 11:50 CET/CESTThe issuer is solely responsible for the content of this announcement.Hamburg, Germany, 21 March 2023:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its preliminary financial results for 2022 on Tuesday, 28 March 2023.The Company is going to hold a conference call to discuss the
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec announces progress in strategic protein degradation partnership with Bristol Myers Squibb 16.03.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement. KEY SCIENTIFIC ACHIEVEMENTS DRIVE THE EXPANSION OF THE PIPELINE OF MOLECULAR GLUE DEGRADERS PERFORMANCE-BASED AND PROGRAMME-BASED PAYMENTS OF IN TOTAL US$ 75 M TO EVOTECHamburg, Germany, 16 March 2023:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, I
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec receives € 150 m loan from European Investment Bank 10.02.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement. FINANCING FOR 3 CORE PILLARS: R&D ACTIVITIES, EQUITY INVESTMENTS AND CONSTRUCTION OF MANUFACTURING FACILITY DEDICATED TO BIOLOGICS, J.POD® TOULOUSE, FRANCE (EU) FOLLOW-ON TO THE EXISTING € 75 M LOAN FACILITY FROM 2017 UNSECURED LOAN FACILITY TAILORED TO STRATEGIC PLANS OF EVOTEC TRANSACTION TO
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec and Related Sciences expand integrated drug discovery and development partnership 09.02.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement. EVOTEC AND RELATED SCIENCES COLLABORATE BY COMBINING COMPLEMENTARY CAPABILITIES TO ADVANCE PORTFOLIOS OF TRANSFORMATIONAL NEW MEDICINES THE PARTNERSHIP OVERSEES A GROWING PORTFOLIO OF MORE THAN 15 MULTI-MODALITY DRUG DISCOVERY PROGRAMMES EXTENSION AND EXPANSION THR
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec SE: Laetitia Rouxel to succeed Enno Spillner as Chief Financial Officer 07.02.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Hamburg, Germany, 07 February 2023:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company's Supervisory Board has appointed Laetitia Rouxel as new Chief Financial Officer and member of the Management Board effe
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec announces agreement with Janssen to develop immune-based therapies 26.01.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement. STRATEGIC PARTNERSHIP LEVERAGES EVOTEC’S EXPERTISE & INTEGRATED PLATFORM FOR DISCOVERY AND DEVELOPMENT Hamburg, Germany, 26 January 2023:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has entered into a str
EQS-News: Evotec SE / Key word(s): Quarter ResultsEvotec SE reports results for the first nine months 2022 and provides corporate update 09.11.2022 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. MULTIPLE NEW AND EXTENDED ALLIANCES IN ALL AREAS PARADIGM SHIFT IN BIOLOGICS STARTING ITS MARKET ENTRY STRATEGY COMMERCIAL LAUNCH OF NEXT-GENERATION MULTI-OMICS DATA ANALYSIS PLATFORM PANHUNTER Hamburg, Germany, 09 November 2022:Evotec SE (Frankfurt Stock Exchange:
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec SE to announce results for the first nine months 2022 on 09 November 2022 03.11.2022 / 11:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Hamburg, Germany, 03 November 2022:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first nine months 2022 on Wednesday, 09 November 2022.The Company is going to hold a conference call to dis
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec completes acquisition of Central Glass Germany 03.11.2022 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement. AS EVOTEC DRUG SUBSTANCE (GERMANY) GMBH, THE ACQUISITION STRENGTHENS EVOTEC’S CLINICAL AND COMMERCIAL DRUG SUBSTANCE MANUFACTURING CAPACITY AND CAPABILITY ESPECIALLY FOR RARE DISEASES AND PRECISION THERAPEUTICS Hamburg, Germany, 03 November 2022:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX,
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec presents paradigm shift in biologics at Capital Markets Day 02.11.2022 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement. TOGETHER FOR MEDICINES THAT MATTER: A PARADIGM SHIFT TO UNLOCK NEW MARKETS AND OPPORTUNITIES FOR GLOBAL ACCESS TO BIOLOGICS BY APPLYING A FULLY INTEGRATED, END-TO-END CONTINUOUS BIOMANUFACTURING PROCESS JUST – EVOTEC BIOLOGICS SELECTED FOR A SECOND AWARD UNDER THE US DEPARTMENT OF DEFEN
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec, CDP Venture Capital and Angelini Ventures launch translational partnership 'Extend' with leading Italian academic Institutions 28.10.2022 / 09:00 CET/CESTThe issuer is solely responsible for the content of this announcement. EXTEND AIMS TO DEVELOP DRUG DISCOVERY PARTNERSHIPS WITH LEADING ACADEMIC INSTITUTIONS FROM ITALY TO ACCELERATE THEIR PROMISING THERAPEUTICS FOR COMMERCIALISATION Hamburg, Germany, 28 October 2022:Evotec SE (Frankfurt St
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec enters partnership with Hannover Medical School to create molecular patient database in autoimmune diseases 25.10.2022 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement. GENERATION OF LONGITUDINAL PANOMICS DATA TO IMPROVE THE DISEASE UNDERSTANDING OF SJÖGREN’S SYNDROME (“SJS”) AND SYSTEMIC LUPUS ERYTHEMATOSUS (“SLE”) HANNOVER MEDICAL SCHOOL (“MHH”) WILL COLLECT BIOSAMPLES FROM SJS AND SLE PATIENTS EVOTEC W
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec launches PanOmics data analysis platform PanHunter at Bio-IT World 18.10.2022 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement. PANHUNTER EMPOWERS ANY SCIENTIST TO ACCESS AND ANALYSE DEEP BIOLOGICAL AND CLINICAL DATA INCLUDING IN PARTICULAR HUGE PANOMICS DATA SETS PANHUNTER ACCELERATES THE R&D PROCESS AND IMPROVES SUCCESS RATES Hamburg, Germany, 18 October 2022:Evotec SE (Frankfurt Stock Exchange: EVT, MD
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec and TIAP expand LAB150 BRIDGE partnership to include Amgen 17.10.2022 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement. AMGEN TO JOIN LAB150 TO BUILD CANADA’S NEXT GENERATION OF LIFE SCIENCE COMPANIES Hamburg, Germany, and Toronto, Canada, 17 October, 2022:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Toronto Innovation Acceleration Partners (“TIAP”) today ann
TORONTO, Canada & HAMBURG, Germany, October 17, 2022--Toronto Innovation Acceleration Partners ("TIAP") and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the two companies have expanded LAB150, their translational BRIDGE partnership, to include Amgen as a strategic partner. The expansion goes along with a combined investment of US$14M to expedite LAB150 programs towards the formation of new companies.
EQS-News: Evotec SE / Key word(s): MiscellaneousJust – Evotec Biologics awarded contract from the U.S. Department of Defense under accelerated antibodies program 20.09.2022 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement. JUST – EVOTEC BIOLOGICS WILL SUPPORT THE DOD WITH RAPID, COST-EFFICIENT DEVELOPMENT OF SAFE, EFFICACIOUS ANTI-PLAGUE MABS EVOTEC WILL PROVIDE PRE-CLINICAL AND CLINICAL TRIAL SERVICES Hamburg, Germany, 20 September 2022:Evotec SE (Frankfurt